Frank McCormick, PhD, FRS, DSc (Hon), outlined the rationale for combining KRAS inhibitors with PI3K and checkpoint inhibitors to improve durability of response.
Frank McCormick, PhD, FRS, DSc (Hon)
Advertisement
Articles by Frank McCormick, PhD, FRS, DSc (Hon)
Frank McCormick, PhD, FRS, DSc (Hon), discussed how RASolute-302 data showing daraxonrasib nearly doubled survival reshaped pancreatic cancer drug development.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Withdrawal Planned for Second-Line Lurbinectedin in SCLC Indication
2
Understanding The Training, Credentialing Landscapes for End-of-Life Doulas
3
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
4
Does Patient Selection Inflate CAR T Outcomes in Multiple Myeloma?
5